Status:
COMPLETED
A Disease Registry of Patients With Mantle Cell Lymphoma
Lead Sponsor:
AstraZeneca
Conditions:
Mantle Cell Lymphoma
Eligibility:
All Genders
18-130 years
Brief Summary
The purpose of this study is to create a patient registry in order to assess treatment patterns, physician reported clinical outcomes and patient-reported health-related quality of life among patients...
Detailed Description
Newer targeted therapies (monotherapy or in combination with other agents) have been recently approved in the United States for the treatment of adult patients with mantle cell lymphoma (MCL) who have...
Eligibility Criteria
Inclusion
- Patient diagnosed with Mantle Cell Lymphoma (MCL)
- Informed consent for participation
- Age ≥ 18 years old, as of the first observed diagnosis of MCL
- Patients for whom a clinical decision has been made to initiate novel therapy in the last 6 months, limited to the following novel agent categories:
- Bcl-2 inhibitors
- BTK inhibitors
- Immunomodulatory agents
- Phosphoinositide 3-kinase inhibitors The novel agent must have been granted approval in at least one haematological cancer. Treatment must be ongoing at the time of enrollment.
Exclusion
- • Patient is participating in a clinical study that prohibits participation in non-interventional studies, or where treatment is blinded, at the time of consent.
Key Trial Info
Start Date :
April 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 18 2024
Estimated Enrollment :
227 Patients enrolled
Trial Details
Trial ID
NCT03816683
Start Date
April 1 2019
End Date
March 18 2024
Last Update
November 14 2025
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Montgomery, Alabama, United States, 36101
2
Research Site
Clovis, California, United States, 93611
3
Research Site
Boulder, Colorado, United States, 80303-1385
4
Research Site
Jacksonville, Florida, United States, 32256